Диссертация (1174352), страница 18
Текст из файла (страница 18)
- 1992. - Vol. 23 (2). - P. 221–223.105.Brenner D., Labreuche J., Poirier O. et al. Renin-angiotensin-aldosteronesystem in brain infarction and vascular death // Ann. Neurol. - 2005. - Vol. 58(1). - P.131-138.109110106. Brophy V.H., Ro S.K., Rhees B.K. et al. Association of phosphodiesterase4D polymorphisms with ischemic stroke in a US population stratified by hypertensionstatus // Stroke. - 2006. - Vol. 37(6).
- P. 1385-1390.107.Brott T.G., Adams H.P., dinger C.P. et al. Measurements of acute cerebralinfarction: a clinical examination scale // Stroke. - 1989. - Vol.20(7). - P. 864 - 870.108. Brown R.D., Whisnant J.P., Sicks J.D. et al. Stroke incidence, prevalence,and survival: secular trends in Rochester, Minnesota, through 1989 // Stroke. - 1996. Vol. 27(3). - P. 373-380.109.Burn J., Dennis M., Bamford J. et al.
Long-term risk of recurrent strokeafter a first-ever stroke. The Oxforshire community stroke project // Stroke. - 1994. Vol. 25. - P. 333-337.110.Burzotta F., Di Castelnuovo A., Amore C. et al. 4G/5G promoter PAI-1gene polymorphism is associated with plasmatic PAI-1 activity in Italians: a model ofgeneenvironment interaction // Thromb.
Haemost. - 1998. - Vol. 79(2). - P. 354-358.111. Buyru N., Altinisik J., Somay G., Ulutin T. Factor V Leiden mutation incerebrovascular disease // Clin. Appl. Thromb. Hemost. - 2005. - Vol. 11(3). - P. 339342.112.Cambien F., Poirier O., Lecerf L. et al. Deletion polymorphism in the genefor angiotensin-converting enzyme is a potent risk factor for myocardial infarction //Nature. - 1992. - Vol.
359(6396). - P. 641-644.113.Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.P., Arveiler D.,Luc G., Bard J.M., Bara L., Ricard S., Tiret L., Amouyel P., Alhenc-Gelas F., SoubrierF. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potentrisk factor for myocardial infarction // Nature. - 1992. - P.641–644.114. Camire R.M., Pollak E.S., Kaushansky K., Tracy P.B. Secretable humanplatelet-derived factor V originates from the plasma pool // Blood. - 1998.
- Vol. 92(9).- P. 3035-3041.115. Carhuapoma J.R. Cerebral venous thrombosis and anticardiolipinantibodies // Stroke. - 1997. - № 12. - P. 2363-2369.116.Carmeliet P., Stassen J.M., Schoonjans L. et al. Plasminogen activatorinhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis// J Clin. Invest. - 1993. - Vol. 92(6). - P. 2756-2760.110111117. Carter A.M., Catto A.J., Bamford J.M., Grant P.J.
Platelet GPIIIa and GPIbvariable number tandem repeat polymorphisms and markers of platelet activation inacute stroke // Arterioscl. Thromb. Vase. Biol. - 1998. - Vol. 18(7). - P. 1124-1131.118. Casas J.P., Hingorami A.D., Bautista L.E., Sharma P. Meta-analysis ofgenetic studies in ischemic stroke: thirty-two genes involving approximately 18,000cases and 58,000 controls // Arch. Neurol. - 2004. - Vol.
61(11). - P. 1652-1661.119.Catto A.J., Carter A.M., Stickland M. et al. Plasminogen activatorinhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects withcerebrovascular disease // Thromb. Haemost. - 1997. - Vol. 77(4). - P. 730-734.120.Chalmers J., MacMahon S., Anderson C. et al. // Clinician's manual onblood pressure and stroke prevention // Second ed. London.
- 2000. - P. 129.121.Chung C.M., Wang R.Y., Chen J.W., et al.. A genomewide associationstudy identifies new loci forACE activity: potential implications for response to ACEinhibitor // Pharmacogenomics J. - 2010. - №10. - P. 537–544.122.Comijs H.C. et al. The course of cognitive decline in older patients //Dement GeriatCogn Dis. - 2004. - №17. - P.
136-142.123. Corbalan R., Tapia J., Braun S. et al. Multidisciplinary study ofcerebrovascular disorders. Cardiovascular profile of occlusive vascular disorders //RevMed. Chil. - 1994. - P.1021-1030.124. Dahabreh I.J., Kitsios G.D., Kent D.M., Trikalinos T.A. Paraoxonase 1polymorphisms and ischemic stroke risk: A systematic review and meta-analysis//Genet. Med. - 2010.
- Vol. 12 (10). - P. 606–615.125. Dahlback B., Hildebrand B. Inherited resistance to activated protein C iscorrected by anticoagulant cofactor activity found to be a property of factor V // Proc.Natl. Acad. Sci. USA. - 1994. - Vol. 91(4). - P. 1396-1400.126.Dawson S., Hamsten A., Wiman B. et al.
Genetic variation at theplasminogen activator inhibitor-1 locus is associated with altered levels of plasminogenactivator inhibitor-1 activity // Arterioscler. Thromb. - 1991. - Vol. 11(1). - P. 183-190.127.Diaz J.F., Hachinski V.C., Pederson L.L., Donald A. Aggregation ofmultiple riskfactors for stroke in siblings of patients with brain infarction and transientischemic attacks // Stroke.
- 1986. - Vol. 17(6). - P. 1239-1242.111112128. Dichgans M. Genetics of ischaemic stroke // Lancet. Neurol. - 2007. - Vol.6 (2). – P. 149–161.129. Dichgans M., Ludwig H., Muller-Hocker J. et al. Small in-frame deletionsand missense mutations in CADASIL: 3D models predict misfolding of Notch3 EGFlike repeat domains // Eur.
J Hum. Genetics. - 2000. - Vol. 8(4). - P. 280-285.130. Dichgans M., Mayer M., Uttner I. et al. The phenotypic spectrum ofCADASIL: clinical findings in 102 cases // Ann. Neurol. - 1998. - Vol. 44 (5). - P. 731–739.131.Dikmen M., Giines H.V., Degirmenci I. Are the angiotensin-convertingenzyme gene and activity risk factors for stroke? // Arq. Neuropsiquiatr. - 2006. - Vol.64(2A).
- P. 211-216.132. Domingues-Montanari S., Mendioroz M., del Rio-Espinola A. et al.Genetics of stroke: a review of recent advances // Expert Rev. Mol. Diagn. - 2008. Vol. 8(4). - P. 495513.133.Dziannot-PabijanD.Plasmin-a2-AntiplasminComplexesinAcuteIschemic Stroke // AdvClinExp Med. - 2006. - №15.
- P. 797-801.134. Esen F.I., Hancer V.S., Kucukkaya R.D., Yesilot N., Coban O., Bahar S.,Tuncay R. Glycoprotein Ib-alpha Kozak polymorphism in ischemic stroke // NeurolRes. - 2012. - № 34. - P. 68-71.135. Fidani L., Clarimon J., Goulas A. et al. Association of phosphodiesterase4D gene GO haplotype and ischaemic stroke in a Greek population // Eur.
J. Neurol. 2007. - Vol. 14(7). - P. 745-749.136.Fitzgerald L.A., Philips D.R. Platelet membrane glycoproteins //Hemostasis and Thrombosis: Basic Principles and Clinical Practice. - 1987. - P. 572593.137. Flossmann E., Schulz U.G., Rothwell P.M. Systematic review of methodsand results of studies of the genetic epidemiology of ischemic stroke // Stroke.- 2004. Vol.
35 (1). - P. 212–227.138. Folcik VA, Smith T, O'Bryant S, Kawczak JA, Zhu, B, Sakurai H,Kajiwara A, Staddon JM, Glabinski, A, Chernosky AL, Tani M, Johnson JM, TuohyVK,Folsom A.R., Prineas R.J., Kaye S.A., Munger R.G. Incidence of hypertension and112113stroke in relation to body fat distribution and other risk factors in older women // Stroke.- 1990. - Vol. 21(5). - P.
701-706.139. Francis G.S. ACE inhibition in cardiovascular disease // N. Engl. J. Med. 2000. - Vol. 342(3). - P. 201-202.140. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis ofcoronary artery disease and the acute coronary syndromes // N. Engl. J. Med. - 1992. Vol.
326(4). - P. 242-250.141. Galinsky D., Tysoe C., Brayne C.E. et al. Analysis of the apo E/apo C-I,angiotensin converting enzyme and methylenetetrahydrofolate reductase genes ascandidates affecting human longevity // Atherosclerosis. - 1997. - Vol. 129(2). - P. 177183.142. Gillum R.F., Gorelick P.B., Cooper E.S.
(eds.) Stroke in Blacks. -1999.- P.230.143. Giovannoni M.P., Cesari N., Graziano A. et al. Synthesis of pyrrolo2,3d.pyridazinones as potent, subtype selective PDE4 inhibitors // J. Enzyme Inhib. Med.Chem. - 2007. - Vol. 22(3). - P. 309-318.144. Gormley K., Bevan S., Markus HS. Polymorphisms in genes of the reninangiotensin system and cerebral small vessel disease // Cerebrovasc. Dis.
- 2007. - Vol.23(2-3). - P. 148-155.145. Graeber M., Muller U. Recent developments in the molecular genetics ofmitochondrial disorders // J. Neurol. Sei. - 1998. - Vol. 153(2). - P. 251-263.146. Gretarsdottir S., Thorleifsson G., Manolescu A. et al. Risk variants foratrial fibrillation on chromosome 4q25 associate with ischemic stroke // Ann. Neurol.
2008. - Vol. 64(4). - P. 402- 409.147. Grossmann R., Geisen U., Merati G. et al. Genetic risk factors in youngadults with, cryptogenic' ischemic cerebrovascular disease // Blood Coagul.Fibrinolysis. - 2002. - Vol. 13(7). - P. 583-590.148. Hachinski VC. The clinical problem of brain and heart.// Stroke. - 1993. №24.
- P. 1-2.149. Hakonarson H. Role of FLAP and PDE4D in myocardial infarction andstroke: target discovery and future treatment options // Curr. Treat. Options Cardiovasc.Med. - 2006. - Vol. 8(3). - P. 183-192.113114150. Hamsten A., de Faire U., Walldius G. et al. Plasminogen activator inhibitorin plasma: Risk factor for recurrent myocardial infarction // Lancet. - 1987. - Vol.2(8549). - P. 3-9.151.Hankey G.J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
